Bio-Thera and Hikma entered into a license and commercialization agreement for STARJEMZA ® in August 2021. Under the terms of the agreement, Bio-Thera is responsible for the development and ...

GUANGZHOU, China and LONDON, May 27, 2025 /PRNewswire/ -- Bio-Thera Solutions, Ltd (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of biosimilars and innovative assets ...

Teva Pharmaceuticals and Alvotech have announced that the US Food and Drug Administration (FDA) has approved the Selarsdi (ustekinumab-aekn) injection as interchangeable with reference biologic ...

Bio-Thera Solutions, Ltd, a commercial-stage biopharmaceutical company developing a pipeline of biosimilars and innovative assets and Hikma Pharmaceuticals PLC, along with its wholly owned subsidiary ...

Patients may now switch between Otulfi and Stelara without requiring a prescription change from a health care provider. The Food and Drug Administration (FDA) has designated Otulfi ® (ustekinumab-aauz ...

The U.S. Food and Drug Administration (FDA) has approved SELARSDI™ (ustekinumab-aekn), a biosimilar to Stelara® (ustekinumab), for treating various conditions including plaque psoriasis, psoriatic ...

GUANGZHOU, China and LONDON, May 27, 2025 /PRNewswire/ -- Bio-Thera Solutions, Ltd (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of biosimilars and innovative assets ...